(Q34597886)

3 August 2017

title

A quercetin containing supplement reduces niacin-induced flush in humans (English)

1 reference

3 August 2017

D Kalogeromitros

1

1 reference

3 August 2017

M Makris

2

1 reference

3 August 2017

C Chliva

3

1 reference

3 August 2017

X Aggelides

4

1 reference

3 August 2017

D Kempuraj

5

1 reference

3 August 2017

T C Theoharides

6

1 reference

3 August 2017

publication date

1 July 2008

1 reference

International Journal of Immunopathology and Pharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

21

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

509-514

1 reference

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Safety of high-dose nicotinamide: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Safety considerations with niacin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

The flavonoid luteolin inhibits niacin-induced flush

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Luteolin and luteolin-7-O-glucoside from dandelion flower suppress iNOS and COX-2 in RAW264.7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Requirement for vasoactive amines for production of delayed-type hypersensitvity skin reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Niacin as a component of combination therapy for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Niacin therapy in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

New perspectives on the use of niacin in the treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100304

10.1177/039463200802100304

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference